9 November 2026 · Updated November 2026 · 11 min read

Types of Exosome Products: Human, Platelet, Plant and Imported Products Compared

Types of exosomes compared: human MSC, platelet, plant and animal sources, how imported products sit under US rules, and what a COA shows for each.

ExosomesTypes of ExosomesExosome SourcesPlant-Derived VesiclesPlatelet-Derived VesiclesImported ProductsCertificate of AnalysisMISEV2023
BB
Cited sources

The types of exosomes sold to practices fall into four source groups: vesicles from human mesenchymal stromal cells, vesicles from human platelets, vesicles from plants, and vesicles from animal sources such as bovine milk. Each group starts from different material, is characterized with different markers and carries different lines on its certificate of analysis, so the source is the first fact to establish about any product.

This guide sets out each source type, how characterization and labeling differ between them, how imported products sit under US rules, and what a certificate of analysis should show for each. The taxonomy is vendor-agnostic and describes products by source and characterization.

Regulatory position

The FDA stated in its 2019 public safety notification that there are no FDA-approved exosome products [2], and its consumer alert, current as of April 2024, states that exosome products intended to treat diseases or conditions in humans require FDA approval [3]. As of 9 November 2026, the FDA list of approved cellular and gene therapy products includes no exosome product [4]. ExaVeyra supplies exosome material for topical aesthetic use by licensed practitioners, described by its available formats. Which material a practice uses, and how, are decisions for the practitioner.

Understanding why the source defines an exosome product

Knauer and colleagues screened 2,394 records in a 2026 scoping review and identified 18 studies of topical exosomes for skin rejuvenation, with sources that included both human and plant-derived vesicles [5]. Their survey of 20 commercial cosmetic products reflected the same variety of sources, with minimal information on isolation, processing or shelf life [5].

MISEV2023, the reporting guideline of the International Society for Extracellular Vesicles, recommends extracellular vesicle (EV) as the generic term and expects every report to define the source, describe the separation and concentration methods and characterize the vesicles [1]. A label that names the source organism and cell type answers the first of those points, and the rest of the documentation answers the others.

MISEV2023 defines exosome as a biogenesis term for vesicles of endosomal origin, a subtype of small EVs, and discourages it unless that subcellular origin can be demonstrated; it also discourages exosome-like vesicles as a name for synthesized EV mimetics [1]. Most commercial preparations are therefore more precisely described as extracellular vesicles, and this guide uses exosome as the market term buyers search for, with vesicle and EV where the literature does.

Gaebe and colleagues rated the certainty of the facial EV evidence as low or very low in a 2026 systematic review of 16 studies and 503 participants, and synthesized the results narratively because of substantial heterogeneity between studies [6]. With that much variation in the material studied, a comparison of products begins with what each one is made from.

Characterizing human mesenchymal stromal cell vesicles by origin and integrity

Many human-derived exosome products start from mesenchymal stromal cells grown in culture, with the vesicles collected from the culture medium. Witwer and colleagues, writing for four scientific societies in 2019, named the diversity of MSCs and their preparation, the range of production and separation methods, and the lack of standardized quality assurance assays among the reasons results disagree across studies [7].

The same group proposed that MSC small EV preparations be defined by quantifiable metrics for cellular origin, the presence of lipid-membrane vesicles and vesicle integrity [7]. Those three headings translate directly into lines a practice can look for in a characterization panel.

Park and colleagues ran a 12-week randomized split-face study in Korea with 28 participants, using a solution containing human adipose tissue stem cell-derived exosomes alongside microneedling, with saline on the control side [8]. The paper shows how a human-source product is described in the literature: tissue of origin, cell type and the comparison used.

Culture conditions belong to the source as well. Pham and colleagues reported in 2021 that bovine vesicles persisted in “exosome-depleted” fetal bovine serum and contaminated human vesicles produced in conditioned medium [9], so a human-derived label is strongest when the supplier also states the culture medium.

Tracing platelet-derived vesicles to donated human platelets

Platelet-derived vesicles are also human in origin, and they come from donated platelets rather than cultured cells. Burnouf and colleagues reviewed allogeneic platelet sources in 2023 and described platelet concentrates from healthy donors, including units past their transfusion date, as source material for platelet lysates and platelet extracellular vesicles [10].

A published study of one commercial topical serum shows how a platelet source is described. Proffer and colleagues reported in 2022 that the serum’s human platelet extract is an allogeneic exosome product derived from US-sourced, leukocyte-reduced apheresed platelets [11]. The six-week study was single-arm and funded by the product’s maker [11].

A platelet source is a human donor, so the donor questions that apply to human tissue apply here too. The FDA’s guidance on donor eligibility for human cells, tissues, and cellular and tissue-based products addresses donor screening and testing under 21 CFR part 1271, subpart C [12], a useful reference for what a supplier can say about the donors behind a lot.

Recognizing plant-derived vesicles as a distinct biology with its own markers

Plant-derived vesicles come from fruit, roots, leaves or plant cell cultures [13, 14, 15]. Dad and colleagues reviewed plant exosome-like nanovesicles in 2021 and described them as carrying plant lipids, proteins and RNA, with morphological and compositional characteristics of their own [16].

Pinedo, de la Canal and de Marcos Lousa called in 2021 for rigor and standardization in plant EV research, noting that most published reports used juicing, grinding or blending methods that rupture plant tissue [13]. They proposed plant EVs as the term for vesicles naturally released into the extracellular space and plant-derived nanovesicles for fractions obtained by destructive processes [13]. A plant label is therefore most useful when it states the species, the plant part or cell line, and whether the vesicles were secreted or produced by tissue disruption.

Characterization follows plant biology. Cho and colleagues characterized vesicles from Rosa damascena callus culture medium in 2026 by nanoparticle tracking, cryo-electron microscopy and western blotting for the plant markers PEN1 and TET8, and several authors were employees of a commercial exosome manufacturer, as the paper discloses [14].

Cho and colleagues, most of them employees of a cosmetics manufacturer, reported in 2021 that ginseng root vesicles carried a lipid profile distinct from the parent root extract [15]. The skin data in both plant studies come from cell models, so these two papers characterize plant vesicles without testing them in people.

Identifying animal-derived vesicles from milk and culture serum

Animal sources appear in two ways. Somiya, Yoshioka and Ochiya described in 2018 a method to isolate highly purified vesicles from bovine milk, a scalable source, and reported spherical vesicles about 120 nanometers in diameter carrying tetraspanins, with biocompatibility studied in a mouse cell line and in mice [17].

The second route is indirect: fetal bovine serum in the medium used to grow human cells, which Pham and colleagues showed can carry bovine vesicles into a human preparation [9]. The FDA’s cosmetics importers page lists bulk shipments of high-risk bovine tissue from countries with bovine spongiform encephalopathy among the subjects of its cosmetics import alerts [18], so an animal-derived ingredient brings sourcing questions of its own.

Comparing the types of exosomes side by side

The table turns the taxonomy into a worksheet. Each row names the starting material, the characterization to request and the documentation lines that fit the source, with the published reference behind each.

Source typeStarting materialCharacterization to requestDocumentation lines that fit the sourceReference
Human MSC-derivedMesenchymal stromal cells grown in culture, tissue of origin statedParticle size and concentration, membrane and tetraspanin markers, morphology, separation methodCell type and tissue, culture medium and any animal serum, donor screening, sterility, endotoxin, mycoplasma[1, 7, 9]
Human platelet-derivedDonated platelets, for example apheresis unitsParticle size and concentration, markers, morphology, separation methodDonor screening and serological testing, collection method, processing steps, sterility, endotoxin[10, 11, 12]
Plant-derivedFruit, roots, leaves or plant cell culturePlant markers such as PEN1 and TET8, particle data, morphologySpecies, plant part or cell line, secreted or produced by tissue disruption, microbial testing[13, 14, 16]
Animal-derivedBovine milk, or bovine serum carried over in cultureParticle data, tetraspanin markers, separation from the milk matrixSpecies and tissue, country of origin of the raw material, sterility, endotoxin[9, 17, 18]
Imported product of any sourceAs stated on the labelThe same panel as its source typeUS category under its label, responsible person, facility registration and product listing where it is sold as a cosmetic[18, 20]

Understanding how imported exosome products are regulated in the United States

When an exosome product is made abroad, for example in Korea, the FDA’s cosmetics importers page sets the baseline: imported cosmetics must comply with the same laws and regulations as those produced domestically, and they are subject to examination at the time of entry [18].

Intended use decides the category. The FDA explains that the law defines drugs in part as articles intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, or intended to affect the structure or any function of the body [19], and its importers page lists anti-aging effects that involve the structure or function of the skin among claims that would cause a product to be regulated as a drug [18].

For a product sold as a cosmetic, the FDA’s page on the Modernization of Cosmetics Regulation Act of 2022 describes facility registration by manufacturers and processors, product listing with ingredients by the responsible person whose name appears on the label, and serious adverse event reporting by that responsible person [20]. Those are the US records a practice can ask about for an imported cosmetic product.

Products for use in humans that fall outside the cosmetic category meet the agency’s position on exosomes. The FDA stated in 2019 that exosomes used to treat diseases and conditions in humans are regulated as drugs and biological products and are subject to premarket review and approval requirements [2].

A comparison of Korean exosomes vs American products is therefore a comparison of documents and labels, with country of manufacture as one fact among several. A product from either origin is assessed on its stated source, its characterization, its per-lot testing and the intended use on its label.

Reading a certificate of analysis for each source type

A certificate of analysis is the lot-level record, and its lines change with the source. Lener and colleagues stated in a 2015 ISEV position paper that vesicle preparations for pharmaceutical use must be tested for viral and microbiological contaminants, including mycoplasma, and must not contain endotoxins above defined levels [21].

  • Every source type: lot number, particle size and concentration with the instrument named, marker results, sterility, endotoxin and mycoplasma, storage temperature and expiry.
  • Human MSC-derived: cell type and tissue of origin, the culture medium and whether it contained animal serum, and the donor screening behind the source tissue.
  • Human platelet-derived: donor screening and serological testing, the collection method, and how the platelet material was processed into vesicles.
  • Plant-derived: species, plant part or cell culture line, whether the vesicles were secreted or produced by tissue disruption, and plant markers.
  • Animal-derived: species and tissue, country of origin of the raw material, and how the vesicles were separated from the starting matrix.

ExaVeyra generates a certificate of analysis for every lot, available on request together with the characterization panel and cold-chain records. Every ExaVeyra certificate reports serological testing for pathogens, and ExaVeyra makes its miRNA characterization data available to qualifying accounts on request.

Understanding what the evidence does not yet show

The literature on source types is growing quickly, and its current limits are worth knowing when two products look alike on paper. Each limit is also a question a practice can ask.

  • No head-to-head comparison of sources: Knauer 2026 called for trials directly comparing sources and delivery methods [5], so the literature does not yet rank one source type above another.
  • Low certainty overall: Gaebe 2026 rated certainty low or very low, with risk of bias moderate to critical for most effectiveness outcomes [6].
  • Plant studies cited here are cell-model work: Cho 2021 and Cho 2026 reported in vitro data [14, 15], and Pinedo 2021 called for standardized plant EV methods [13].
  • Platelet evidence is early: Proffer 2022 had no comparison group and was funded by the product’s maker [11].
  • Milk vesicles have been studied mainly in cells and mice: Somiya 2018 reported biocompatibility work [17], with no topical aesthetic data in this reference set.
  • Identity is reported unevenly: Knauer 2026 found little isolation or processing information on commercial products [5].

Questions to ask about any exosome product

  • What is the source organism, tissue and cell type, and does the label state it?
  • How were the vesicles separated, and which instruments measured size and concentration?
  • Which markers were tested, and do they fit the source (tetraspanins for a mammalian source, plant markers such as PEN1 and TET8 for a plant source)?
  • Was animal serum used in culture, and how was carry-over addressed?
  • For a human source, what donor screening and serological testing applied?
  • Is a certificate of analysis available for the specific lot, with sterility, endotoxin and mycoplasma results?
  • For an imported product, what US category is it sold under, who is the responsible person on the label, and what does the label state about intended use?
  • At what temperature does it ship and store, and are cold-chain records available for the lot?

Choosing a documented source with confidence

Every source type described here can be documented well, and a practice that asks for the source, the characterization and the lot record will find the comparison straightforward. ExaVeyra supplies exosome material to licensed practitioners: it ships frozen from the manufacturing facility on dry ice in all available formats, each lot carries its lot number, and a certificate of analysis is generated for every lot and available on request with the characterization panel and cold-chain records. Anyone can apply for an account or ask the scientific team a question without an NPI, and NPI verification unlocks the practitioner portal, exclusive resources and pricing. Practices ready to compare can apply today or send the scientific team a question about any source type.

Educational Disclaimer: This article is for educational purposes only and does not constitute medical or legal advice. It does not identify any material, compound, device setting or protocol as safe, effective or appropriate for any patient, and it is not intended to diagnose, treat, cure, or prevent any disease. Questions about a treatment belong with the reader’s own licensed provider. Exosome material is supplied for topical aesthetic use by licensed practitioners. No exosome product is FDA-approved for any use, and ExaVeyra Sciences makes no statement about administration, route, or outcome. Compounded medications are not FDA-approved. They are prepared by a 503A compounding pharmacy licensed by the Texas State Board of Pharmacy for an individual patient against that patient’s prescription, and are available to NPI-verified licensed practitioners only, in the states where the pharmacy is licensed. Product, device and brand names mentioned are trademarks of their respective owners and are used only to identify the products discussed. Their mention is not an endorsement, and those owners have not reviewed or endorsed this article. ExaVeyra Sciences is a supplier and takes no part in any diagnosis, treatment decision, or plan of care. Findings described are attributed to the peer-reviewed literature, trial registries and agencies cited. The content of these guides is provided for general informational purposes only. It does not constitute legal, medical, or regulatory advice, and does not establish that any particular product or practice is compliant. Regulatory requirements vary by state and depend on the circumstances of each practice. Each practitioner should consult their own legal counsel and the applicable state licensing boards before acting on anything stated here.

References

  1. 1.Welsh JA, Goberdhan DCI, O'Driscoll L, Buzas EI, Blenkiron C, Bussolati B, et al; MISEV Consortium; Théry C, Witwer KW. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. J Extracell Vesicles. 2024;13(2):e12404. PMID 38326288. PMC10850029. doi:10.1002/jev2.12404International Society for Extracellular Vesicles reporting guideline, compiled from task forces and feedback from more than 1,000 researchers. Carries in this article: the generic term extracellular vesicle; exosome as a biogenesis term (endosomal origin, a subtype of small EVs) discouraged unless subcellular origin is demonstrated; exosome-like vesicles discouraged for synthesized EV mimetics; and the expectation that reports define sources and describe separation and characterization. Disclosure: many consortium authors list EV company affiliations, declared in the article.
  2. 2.U.S. Food and Drug Administration. Public Safety Notification on Exosome Products. December 6, 2019 (content current as of 12/06/2019; verified 9 November 2026). https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/public-safety-notification-exosome-productsAgency safety notification (CBER). Carries in this article: the statement that there are currently no FDA-approved exosome products, and the agency position that exosomes used in humans for diseases and conditions are regulated as drugs and biological products subject to premarket review.
  3. 3.U.S. Food and Drug Administration. Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. Content current as of 04/09/2024; verified 9 November 2026. https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/consumer-alert-regenerative-medicine-products-including-stem-cells-and-exosomesAgency consumer alert (CBER). Carries in this article: the FDA statement that exosome products intended to treat diseases or conditions in humans require FDA approval, in the regulatory callout.
  4. 4.U.S. Food and Drug Administration. Approved Cellular and Gene Therapy Products. Content current as of 10/30/2026; verified 9 November 2026. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-productsAgency list of licensed cellular and gene therapy products (CBER). Carries in this article: as of 9 November 2026 the list includes no exosome or extracellular vesicle product, the basis for the dated regulatory status in the callout and FAQ.
  5. 5.Knauer G, Chang A, Gupta A, Brownstone N, Mejia N, Bauman S, et al. Clinical Evidence and Commercial Landscape of Topical Exosomes for Skin Rejuvenation: A Scoping Review. Aesthet Surg J. 2026;46(11):NP148-NP157. PMID 42411735. doi:10.1093/asj/sjag141Scoping review (2,394 records screened, 18 studies of topical exosomes for skin rejuvenation) plus a survey of the first 20 commercial cosmetic exosome products in a shopping search. Carries in this article: the studies and products span human and plant-derived sources, the products carried minimal information on isolation, processing or shelf life, and the authors call for trials directly comparing sources. Disclosure: academic authors (USA); no COI statement in the PubMed record.
  6. 6.Gaebe K, Lowe K, Bosnalie D, Khoury S, Villemure Poliquin N, Nichols A. Effectiveness and Safety of Extracellular Vesicle-Based Therapies for Nonsurgical Facial Rejuvenation: A Systematic Review. Facial Plast Surg Aesthet Med. 2026. Published online ahead of print. PMID 42487416. doi:10.1177/26893614261457879PRISMA systematic review with GRADE assessment; 16 studies, 503 participants. Carries in this article: certainty of evidence rated low or very low, risk of bias moderate to critical for most effectiveness outcomes, and narrative synthesis because of substantial heterogeneity. Disclosure: academic authors (Canada); no COI statement in the PubMed record.
  7. 7.Witwer KW, Van Balkom BWM, Bruno S, Choo A, Dominici M, Gimona M, et al. Defining mesenchymal stromal cell (MSC)-derived small extracellular vesicles for therapeutic applications. J Extracell Vesicles. 2019;8(1):1609206. PMID 31069028. PMC6493293. doi:10.1080/20013078.2019.1609206Consensus position statement of four societies (SOCRATES, ISEV, ISCT, ISBT). Carries in this article: the diversity of MSCs and their preparation, production and separation methods and quality assays as reasons results disagree, and the proposal to define MSC vesicle preparations by cellular origin, presence of lipid-membrane vesicles and vesicle integrity. Disclosure: some members hold EV company interests, declared in the full text.
  8. 8.Park GH, Kwon HH, Seok J, Yang SH, Lee J, Park BC, et al. Efficacy of combined treatment with human adipose tissue stem cell-derived exosome-containing solution and microneedling for facial skin aging: A 12-week prospective, randomized, split-face study. J Cosmet Dermatol. 2023;22(12):3418-3426. PMID 37377400. doi:10.1111/jocd.15872Prospective randomized split-face study over 12 weeks, saline with microneedling on the control side; adults in Korea; n = 28. Carries in this article: an example of how a human-source product made in Korea is described in the literature (tissue of origin, cell type, comparison). Funding: National Research Foundation of Korea grants listed in the PubMed record; no COI statement in the record.
  9. 9.Pham CV, Midge S, Barua H, Zhang Y, Ngoc-Gia Nguyen T, Barrero RA, et al. Bovine extracellular vesicles contaminate human extracellular vesicles produced in cell culture conditioned medium when 'exosome-depleted serum' is utilised. Arch Biochem Biophys. 2021;708:108963. PMID 34126088. doi:10.1016/j.abb.2021.108963Experimental study with a literature survey (human and rodent EV publications 2015 to 2019; 'exosome-depleted serum' used in 46 percent); nanoparticle tracking with detergent lysis and bovine CD9 ELISA. Carries in this article: bovine vesicles persist in 'exosome-depleted' serum and contaminate human vesicles made in conditioned medium, so the culture medium is part of a human-source label. Disclosure: two co-authors list a biomedicine company affiliation; no product was evaluated.
  10. 10.Burnouf T, Chou ML, Lundy DJ, Chuang EY, Tseng CL, Goubran H. Expanding applications of allogeneic platelets, platelet lysates, and platelet extracellular vesicles in cell therapy, regenerative medicine, and targeted drug delivery. J Biomed Sci. 2023;30(1):79. PMID 37704991. PMC10500824. doi:10.1186/s12929-023-00972-wNarrative review of allogeneic platelet biomaterials. Carries in this article: platelet concentrates collected from healthy donors, including units past their transfusion date, as source material for platelet lysates and platelet extracellular vesicles. Disclosure: the first author is an inventor on university-owned patents and a founder of a platelet lysate start-up company, per the PubMed COI statement.
  11. 11.Proffer SL, Paradise CR, DeGrazia E, Halaas Y, Durairaj KK, Somenek M, et al. Efficacy and Tolerability of Topical Platelet Exosomes for Skin Rejuvenation: Six-Week Results. Aesthet Surg J. 2022;42(10):1185-1193. PMID 35689936. doi:10.1093/asj/sjac149Prospective, single-arm, non-randomized study of a topical platelet-derived serum within a standardized home skin care regimen, evaluated at baseline and 6 weeks with 3D imaging. Carries in this article: the abstract describes the human platelet extract in the commercial topical serum studied as an allogeneic exosome product derived from US-sourced, leukocyte-reduced apheresed platelets; single-arm, so it has no comparison group. Disclosure: funded by the product maker (Europe PMC grant record); two authors list affiliations with the product maker.
  12. 12.U.S. Food and Drug Administration. Eligibility Determination for Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products. Guidance for Industry, August 2007 (content current as of 05/02/2024; verified 9 November 2026). Docket FDA-2004-D-0225. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/eligibility-determination-donors-human-cells-tissues-and-cellular-and-tissue-based-productsAgency guidance (CBER) on donor eligibility under 21 CFR part 1271, subpart C. Carries in this article: donor screening and testing requirements under 21 CFR part 1271, subpart C, cited solely as a reference point for asking what applied to the donors behind a human-source lot.
  13. 13.Pinedo M, de la Canal L, de Marcos Lousa C. A call for Rigor and standardization in plant extracellular vesicle research. J Extracell Vesicles. 2021;10(6):e12048. PMID 33936567. PMC8077130. doi:10.1002/jev2.12048Letter to the journal (no abstract), plant EV research field. Carries in this article: most published plant reports used juicing, grinding or blending methods that rupture tissue; the authors propose plant EVs for naturally released vesicles and plant-derived nanovesicles for fractions from destructive processes, so a plant label should state source and method. Disclosure: academic authors (Argentina, UK).
  14. 14.Cho BS, Lee HJ, Son B, Lee E, Moon SY, Shin E, et al. Characterization of Rosa damascena Callus-Derived Exosome-like Vesicles and Their Multifunctional Activities in Skin-Related Cellular Models. Int J Mol Sci. 2026;27(11):4938. PMID 42278464. PMC13256896. doi:10.3390/ijms27114938In vitro characterization study (nanoparticle tracking, cryo-electron microscopy, western blot, proteomics, small RNA sequencing) of rose callus culture vesicles compared with crude conditioned medium. Carries in this article: plant vesicles characterized with the plant markers PEN1 and TET8; cell-model data only. Disclosure: several authors were employed by a commercial exosome manufacturer, and one is its chief executive and a shareholder, per the PubMed COI statement.
  15. 15.Cho EG, Choi SY, Kim H, Choi EJ, Lee EJ, Park PJ, et al. Panax ginseng-Derived Extracellular Vesicles Facilitate Anti-Senescence Effects in Human Skin Cells: An Eco-Friendly and Sustainable Way to Use Ginseng Substances. Cells. 2021;10(3):486. PMID 33668388. PMC7996359. doi:10.3390/cells10030486In vitro study with LC-MS lipidomics (188 lipid species) of ginseng root and ginseng cell culture vesicles on human skin cells. Carries in this article: ginseng root vesicles have a lipid profile distinct from the parent root extract; the skin data are from cell models. Disclosure: seven of nine authors are employees of a cosmetics manufacturer, per the PubMed COI statement.
  16. 16.Dad HA, Gu TW, Zhu AQ, Huang LQ, Peng LH. Plant Exosome-like Nanovesicles: Emerging Therapeutics and Drug Delivery Nanoplatforms. Mol Ther. 2021;29(1):13-31. PMID 33278566. PMC7791080. doi:10.1016/j.ymthe.2020.11.030Narrative review of plant exosome-like nanovesicles: origin, isolation, composition and cargo. Carries in this article: plant vesicles carry plant lipids, proteins and RNA with morphological and compositional characteristics of their own. Disclosure: the authors declare no competing interests.
  17. 17.Somiya M, Yoshioka Y, Ochiya T. Biocompatibility of highly purified bovine milk-derived extracellular vesicles. J Extracell Vesicles. 2018;7(1):1440132. PMID 29511463. PMC5827637. doi:10.1080/20013078.2018.1440132Methods and biocompatibility study in a mouse macrophage cell line and in mice. Carries in this article: bovine milk as a scalable vesicle source, the difficulty of isolating pure vesicles from the milk matrix, and the reported spherical vesicles of about 120 nm carrying tetraspanin markers. Disclosure: no conflict of interest reported by the authors.
  18. 18.U.S. Food and Drug Administration. Cosmetics Importers. Content current as of 11/18/2025; verified 9 November 2026. https://www.fda.gov/cosmetics/cosmetics-international-activities/cosmetics-importersAgency question-and-answer page for importers. Carries in this article: imported cosmetics must comply with the same laws and regulations as domestic ones and are subject to examination at entry; many countries define cosmetics and drugs differently, and anti-aging claims involving the structure or function of the skin would make a product a drug in the United States; import alerts cover bulk shipments of high-risk bovine tissue from BSE countries.
  19. 19.U.S. Food and Drug Administration. Is It a Cosmetic, a Drug, or Both? (Or Is It Soap?). Content current as of 09/11/2024; verified 9 November 2026. https://www.fda.gov/cosmetics/cosmetics-laws-regulations/it-cosmetic-drug-or-both-or-it-soapAgency explainer on the FD&C Act definitions. Carries in this article: whether a product is a cosmetic or a drug is determined by its intended use, and the statutory drug definition quoted in the import section.
  20. 20.U.S. Food and Drug Administration. Modernization of Cosmetics Regulation Act of 2022 (MoCRA). Content current as of 10/29/2026; verified 9 November 2026. https://www.fda.gov/cosmetics/cosmetics-laws-regulations/modernization-cosmetics-regulation-act-2022-mocraAgency overview page. Carries in this article: facility registration by manufacturers and processors (a facility includes an establishment of an importer), product listing with ingredients and serious adverse event reporting by the responsible person named on the label, as the US records a practice can ask about for an imported cosmetic.
  21. 21.Lener T, Gimona M, Aigner L, Börger V, Buzas E, Camussi G, et al. Applying extracellular vesicles based therapeutics in clinical trials - an ISEV position paper. J Extracell Vesicles. 2015;4:30087. PMID 26725829. PMC4698466. doi:10.3402/jev.v4.30087Position paper of the International Society for Extracellular Vesicles and an EU COST action. Carries in this article: sterile vesicle preparations for pharmaceutical use must be tested for viral and microbiological contaminants, including mycoplasma, and must not contain endotoxins above defined levels; the safety lines expected on a COA for every source type. Disclosure: consensus authorship includes academic, regulatory and some industry-affiliated members.

Ask your practitioner how their exosomes are tested

Lab analysis shows what is in a lot: particle counts, vesicle markers, sterility and how the material was stored. A practice that sources carefully can answer these questions from its supplier’s records.

Frequently Asked Questions

What are the different types of exosomes?
Exosome products are grouped by source: human mesenchymal stromal cell vesicles, human platelet-derived vesicles, plant-derived vesicles and animal-derived vesicles such as those from bovine milk. Knauer and colleagues reported in a 2026 scoping review that both the studies and the commercial products they surveyed spanned human and plant sources, and MISEV2023 recommends extracellular vesicle as the generic term and asks every report to define the source, separation method and characterization.
Are exosomes from humans?
Many are. Human-derived products usually start from mesenchymal stromal cells grown in culture or from donated platelets, and Witwer and colleagues proposed in a 2019 four-society statement that MSC small EV preparations be defined by cellular origin, the presence of lipid-membrane vesicles and vesicle integrity. Other products come from plants or animal sources, and the label should state which.
Are exosomes plant based?
Some are. Plant-derived vesicles come from fruit, roots, leaves or plant cell cultures, and Cho and colleagues characterized rose callus culture vesicles in 2026 with the plant markers PEN1 and TET8. Pinedo and colleagues noted in 2021 that most published plant reports used juicing, grinding or blending methods that rupture plant tissue, so a plant label should state the species and the method.
Where are platelet-derived exosomes sourced from?
From donated human platelets. Burnouf and colleagues described in 2023 platelet concentrates from healthy donors, including units past their transfusion date, as source material for platelet lysates and platelet extracellular vesicles. Proffer and colleagues reported in 2022 that the platelet extract in one commercial topical serum is derived from US-sourced, leukocyte-reduced apheresed platelets, in a single-arm study funded by the product’s maker.
Korean exosomes vs American: what is the difference?
Country of manufacture is one fact among several; source, characterization, per-lot testing and labeled intended use decide the comparison. The FDA’s cosmetics importers page states that imported cosmetics must comply with the same US laws and regulations as domestic ones, and lists anti-aging effects that involve the structure or function of the skin among claims that would cause a product to be regulated as a drug.
How should I compare exosome brands?
Compare the documents behind each brand: source organism and cell type, separation method, particle size and concentration, markers, per-lot sterility, endotoxin and mycoplasma results, labeling and storage. Gaebe and colleagues rated the facial vesicle evidence as low or very low certainty in a 2026 systematic review and found the studies too heterogeneous to pool, so data from one product cannot be assumed to apply to another.
What should a COA show for each type of exosome?
Every certificate should give the lot number, particle size and concentration with the instrument named, markers, sterility, endotoxin and mycoplasma. Lener and colleagues stated in a 2015 ISEV position paper that vesicle preparations for pharmaceutical use must be tested for microbiological contaminants, including mycoplasma, and kept below defined endotoxin levels. A human source adds donor screening and culture medium, a plant source adds species, method and plant markers, and an animal source adds species and country of origin.
How are imported exosome products regulated in the US?
The category follows intended use. The FDA explains that intended use determines whether a product is a cosmetic or a drug, its MoCRA page describes facility registration, product listing and adverse event reporting for cosmetics, and the agency stated in 2019 that there are no FDA-approved exosome products; its list of approved cellular and gene therapy products, checked 9 November 2026, still includes none. Imported cosmetics are held to the same US laws and regulations as domestic ones.

ExaBlog Weekly for licensed practices

One email a week for licensed practices: new ExaBlog research reviews, practice guides and regulatory updates, each article citing its sources.

We write in English unless you check this box.

No spam. Unsubscribe any time.